ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Senate Appropriators Reject President’s $228 Million Increase For Cancer Research; House and Senate Report Language

September 18, 2009

Center Seeks HER-2 Positive Breast Cancer Patients

August 29, 2003

In Brief: With Opening of New 13-Story Hospital, M.D. Anderson Now 4.1 M Sq. Feet

January 22, 1999

Docetaxel As Adjuvant Therapy Shows Benefit Over Standard

June 28, 2002

NCI Director Klausner Resigns To Head Institute Begun By AOL Chairman Case.

September 14, 2001

Older Women More Likely To Receive Lower Chemotherapy Doses, Study Finds

August 28, 2009